ES2061166T3 - Moleculas ligantes labiles por acido. - Google Patents

Moleculas ligantes labiles por acido.

Info

Publication number
ES2061166T3
ES2061166T3 ES91203439T ES91203439T ES2061166T3 ES 2061166 T3 ES2061166 T3 ES 2061166T3 ES 91203439 T ES91203439 T ES 91203439T ES 91203439 T ES91203439 T ES 91203439T ES 2061166 T3 ES2061166 T3 ES 2061166T3
Authority
ES
Spain
Prior art keywords
low
aralquilo
bajo
alkylene
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91203439T
Other languages
English (en)
Inventor
Petrus Johannes Boon
Franciscus Michael Kaspersen
Ebo Sybren Bos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2061166T3 publication Critical patent/ES2061166T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Mushroom Cultivation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCION SE REFIERE AL CAMPO DE LA INMUNOTERAPIA DEL CANCER, MAS ESPECIFICAMENTE A INMUNOCONJUGADOS DE MEDIO CITITOXICO CON UN MEDIO OBJETIVO, Y MAS ESPECIFICAMENTE A INMUNOCONJUGADOS DE ANTICUERPOS O FRAGMENTOS O DERIVADOS FUNCIONALES DE ANTICUERPOS ACOPLADOS A UNA SUSTANCIA CITOTOXICA TALES COMO DROGAS, TOXINAS O RADIOISOTOPOS. ESPECIALMENTE SE REFIERE A LA EMISION DE SUSTANCIAS LIGADAS A UN MEDIO OBJETIVO A TRAVES DE LA UTILIZACION DE MOLECULAS ENLACE CON ACIDO DERIVADOS DE COMPUESTOS DE LA FORMULA I: DONDE: R1 = H, ALQUILO BAJO, ALQUILO -N-BAJO; ALQUILO -O-BAJO; ALQUILO -S-BAJO; ARALQUILO -O-BAJO; ARALQUILO -S-BAJO; ARALQUILO -N-BAJO; ALQUILENO -O-BAJO; ALQUILENO -N-BAJO; ALQUILENO -S-BAJO; ARILO -N-BAJO: ARILO -O-BAJO; ARILO -S-BAJO; R2 = H, ALQUILO BAJO; ARALQUILO BAJO; ARILO BAJO; R3 ES: U OTRA ESTRUCTURA QUIMICA QUE SEA CAPAZ DE DECOLIZAR EL PAR DE ELECTRONES IONICOS DEL NITROGENO Y R4 ES UN GRUPO ACTIVO, CAPAZ DE LIGAR R3 A UNA MOLECULA PORTADORA, UNA SUSTANCIA PROTEINICA, UNANTICUERPO (FRAGMENTO), UN POLIMERO O UN ACIDO NUCLEICO.
ES91203439T 1990-12-31 1991-12-30 Moleculas ligantes labiles por acido. Expired - Lifetime ES2061166T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203526 1990-12-31

Publications (1)

Publication Number Publication Date
ES2061166T3 true ES2061166T3 (es) 1994-12-01

Family

ID=8205218

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91203439T Expired - Lifetime ES2061166T3 (es) 1990-12-31 1991-12-30 Moleculas ligantes labiles por acido.

Country Status (17)

Country Link
US (1) US5306809A (es)
EP (1) EP0495265B1 (es)
JP (1) JPH04334377A (es)
KR (1) KR920012063A (es)
AT (1) ATE109476T1 (es)
AU (1) AU646121B2 (es)
CA (1) CA2058595A1 (es)
DE (1) DE69103255T2 (es)
DK (1) DK0495265T3 (es)
ES (1) ES2061166T3 (es)
FI (1) FI101678B1 (es)
HU (1) HUT60484A (es)
IE (1) IE65406B1 (es)
NO (1) NO180417C (es)
NZ (1) NZ241217A (es)
PT (1) PT99954B (es)
ZA (1) ZA9110203B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0638583A1 (en) * 1993-08-13 1995-02-15 Hoechst Aktiengesellschaft Aminosugar active substances, a process for their preparation and use as pharmaceuticals
DE4433890C2 (de) * 1994-09-22 1999-02-18 Deutsches Krebsforsch Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
ATE234635T1 (de) * 1995-12-22 2003-04-15 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6800616B2 (en) * 1998-02-26 2004-10-05 Supergen, Inc. Treatment of HIV infections
CA2248592A1 (en) * 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
TWI242000B (en) * 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
US6140015A (en) * 1998-12-10 2000-10-31 International Business Machines Corporation Photoresist compositions with pendant polar-functionalized aromatic groups and acid-labile branching
CA2358420C (en) * 1999-03-11 2010-03-16 Ardenia Investments Ltd. New compounds for the treatment of cancer
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
HUP0303719A2 (hu) * 2000-10-16 2004-03-01 Neopharm, Inc. Mitoxantron hatóanyag-tartalmú liposzómás gyógyszerkészítmények és eljárás az előállításukra
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
GB0116143D0 (en) * 2001-07-02 2001-08-22 Amersham Pharm Biotech Uk Ltd Chemical capture reagent
KR100507968B1 (ko) * 2001-08-18 2005-08-17 한국과학기술연구원 자기집합체를 형성하는 항암제-키토산 복합체 및 그의제조방법
CA2822457C (en) * 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
JP2005529080A (ja) * 2002-03-08 2005-09-29 エモリー　ユニバーシティ 腫瘍の増殖および脈管形成のサプレッサとしての新規のクルクミノイド−第ＶＩＩａ因子構築物
WO2003100081A2 (en) * 2002-05-24 2003-12-04 Mirus Corporation Biologically active maleamic acid derivatives with labile amide bonds
CN1733314A (zh) * 2004-08-11 2006-02-15 张阳德 半乳糖化白蛋白磁性阿霉素纳米粒的制备方法
EP1809671B1 (en) * 2004-11-09 2014-07-16 University Of Southern California CpG/antibody conjugate against cancer
ES2408704T3 (es) 2005-01-05 2013-06-21 Biogen Idec Ma Inc. Moléculas de unión a Cripto
KR20090091145A (ko) 2006-10-27 2009-08-26 웨이-치앙 션 지질화된 인터페론 및 이의 용도
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) * 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
WO2010011684A2 (en) * 2008-07-21 2010-01-28 The Regents Of The University Of California Prodrug and fluoregenic compositions and methods for using the same
JP5472288B2 (ja) * 2009-03-17 2014-04-16 国立大学法人 東京大学 タンパク質の電荷調節剤、及びタンパク質内包高分子ミセル複合体
US8535948B2 (en) * 2009-03-26 2013-09-17 Institute For Systems Biology Method to determine protein interaction sites
JP2012531212A (ja) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
SG181814A1 (en) 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
RU2013103763A (ru) 2010-07-02 2014-08-10 Ангиохем Инк. Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
CN103890246A (zh) 2011-08-18 2014-06-25 亲和生物科学公司 可溶性多肽
MX350378B (es) 2012-01-10 2017-09-05 Biogen Ma Inc Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
WO2014057436A2 (en) 2012-10-10 2014-04-17 Adamed Sp. Z O.O. Anticancer conjugate
CA2895284A1 (en) 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
WO2015123595A1 (en) 2014-02-14 2015-08-20 The Regents Of The University Of California Cyclic peroxides as prodrugs for selective delivery of agents
CN106999444B (zh) 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3554638B1 (en) 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
WO2020081174A1 (en) 2018-10-16 2020-04-23 Nant Holdings Ip, Llc Alpha emitter compositions and methods
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
JP2025503700A (ja) * 2022-01-14 2025-02-04 レジェネロン ファーマシューティカルズ， インコーポレイテッド ベルカリンａ誘導体及びその抗体薬物複合体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4744981A (en) * 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5140013A (en) * 1989-11-28 1992-08-18 Universite Laval Maleic anhydride derivatives used as conjugation agents of anti-tumor agents on desired carriers

Also Published As

Publication number Publication date
KR920012063A (ko) 1992-07-25
AU646121B2 (en) 1994-02-10
IE65406B1 (en) 1995-10-18
NO180417B (no) 1997-01-06
DE69103255T2 (de) 1994-12-08
PT99954B (pt) 1999-06-30
DK0495265T3 (da) 1995-01-02
DE69103255D1 (de) 1994-09-08
EP0495265A1 (en) 1992-07-22
ATE109476T1 (de) 1994-08-15
JPH04334377A (ja) 1992-11-20
US5306809A (en) 1994-04-26
CA2058595A1 (en) 1992-07-01
IE914567A1 (en) 1992-07-01
NO920040D0 (no) 1992-01-02
FI101678B (fi) 1998-08-14
PT99954A (pt) 1993-06-30
FI916131A0 (fi) 1991-12-27
NO180417C (no) 1997-04-16
NO920040L (no) 1992-07-01
ZA9110203B (en) 1993-01-27
FI101678B1 (fi) 1998-08-14
HU914133D0 (en) 1992-03-30
AU9009891A (en) 1993-01-28
EP0495265B1 (en) 1994-08-03
FI916131A7 (fi) 1992-07-01
NZ241217A (en) 1993-12-23
HUT60484A (en) 1992-09-28

Similar Documents

Publication Publication Date Title
ES2061166T3 (es) Moleculas ligantes labiles por acido.
ATE337305T1 (de) Halogenfreie ionische flüssigkeiten
UY27431A1 (es) Compuestos químicos
NO20032829D0 (no) Kjemiske forbindelser
UY27435A1 (es) Compuestos químicos
ATE256681T1 (de) N-heterozyklische derivate als nos inhibitoren
ES2129679T3 (es) Derivados que contienen el grupo amidino, utiles como inhibidores de la sintasa de oxido nitrico.
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
ES8403439A1 (es) Procedimiento para preparar derivados de amidas.
EA199900604A1 (ru) Производные арилсульфониламиногидроксамовой кислоты
ES8306123A1 (es) Procedimiento para la obtencion de derivados de imidazol trisustituidos.
EA202192753A1 (ru) Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме
ES8301210A1 (es) Un procedimiento para la preparacion de un derivado del indol.
BR9914998A (pt) Antibióticos macrólidos
IT1263089B (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
ES482598A1 (es) Un procedimiento para la preparacion de n-(diaminofosfinil) aril-carboxamidas.
ATE354622T1 (de) Flüssigkristallines medium
ES8306750A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroariltiazoles.
DE69634961D1 (de) Neue zyklische depsipeptid pf1022 derivate
CY1106055T1 (el) Τυποποιηση των υποκατεστημενων βενζιμιδαζολων
CY1118131T1 (el) Φαρμακο δραστικο στο νευροπαθητικο αλγος
EA202190298A1 (ru) Циклические динуклеотиды в качестве агонистов sting
ES8304145A1 (es) "procedimiento para la preparacion de nuevas amidas de acidos carboxilicos".
ES8301883A1 (es) Procedimiento para la preparacion de derivados de ciclohexe-no

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 495265

Country of ref document: ES